Heart failure with preserved ejection fraction in women: the Dutch Queen of Hearts programReportar como inadecuado

Heart failure with preserved ejection fraction in women: the Dutch Queen of Hearts program - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Netherlands Heart Journal

, Volume 23, Issue 2, pp 89–93

First Online: 23 January 2015DOI: 10.1007-s12471-014-0613-1

Cite this article as: den Ruijter, H., Pasterkamp, G., Rutten, F.H. et al. Neth Heart J 2015 23: 89. doi:10.1007-s12471-014-0613-1


Heart failure HF poses a heavy burden on patients, their families and society. The syndrome of HF comes in two types: with reduced ejection fraction HFrEF and preserved ejection fraction HFpEF. The latter is on the increase and predominantly present in women, especially the older ones. There is an urgent need for mortality-reducing drugs in HFpEF, a disease affecting around 5 % of those aged 65 years and over. HFpEF develops in patients with risk factors and comorbidities such as obesity, hypertension, diabetes, COPD, but also preeclampsia. These conditions are likely to drive microvascular disease with involvement of the coronary microvasculature, which may eventually evolve into HFpEF. Currently, the diagnosis of HFPEF relies mainly on echocardiography. There are no biomarkers that can help diagnose female microvascular disease or facilitate the diagnosis of early stages of HFpEF. Recently a Dutch consortium was initiated, Queen of Hearts, with support from the Netherlands Heart Foundation, with the aim to discover and validate biomarkers for diastolic dysfunction and HFpEF in women. These biomarkers come from innovative blood-derived sources such as extracellular vesicles and circulating cells. Within the Queen of Hearts consortium, we will pursue female biomarkers that have the potential for further evolution in assays with point of care capabilities. As a spin-off, the consortium will gain knowledge on gender-specific pathology of HFpEF, possibly opening up novel treatment options.

KeywordsHeart failure with preserved ejection fraction Gender  Download fulltext PDF

Autor: H. den Ruijter - G. Pasterkamp - F. H. Rutten - C. S. P. Lam - C. Chi - K. H. Tan - A. J. van Zonneveld - M. Spaand

Fuente: https://link.springer.com/

Documentos relacionados